Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Salt Lake City, Utah 84112


There is now strong evidence from clinical trials that carvedilol therapy in heart failure is superior to therapy with metoprolol. Not only does carvedilol have superior effects on lipid profiles, insulin sensitivity, renal blood flow, and reversal of pathologic remodeling but also its use is associated with fewer deaths compared to metoprolol. These facts make it important to carefully define how metoprolol and carvedilol are pharmacologically different. One potential difference is α1-AR antagonism. If we demonstrate that these α1-AR effects are preserved with chronic therapy, then α1-AR blockade may have an important role in carvedilol favorably altering the natural history of heart failure. On the other hand, if we demonstrate that tolerance to the α1-AR blockade effect of carvedilol decreases with time, then it would be unlikely that this pharmacologic property contributes to the efficacy of carvedilol. In such a case other pharmacologic properties, such as antioxidant activity, would appear to be important. These results will help guide future studies into CHF and AR blockade.


Inclusion Criteria: 1. Age of 18 to 85 years 2. Symptomatic heart failure, NYHA class I to III 3. Left ventricular ejection fraction < 0.40 4. Give written informed consent Exclusion Criteria: 1. active myocarditis 2. congenital heart disease 3. uncorrected, hemodynamically significant stenotic valvular disease 4. hypertrophic cardiomyopathy 5. Asthma or other obstructive airway diseases requiring bronchodilators 6. Heart rate < 60 beats/min, supine systolic blood pressure < 85 mm Hg, supine diastolic blood pressure > 90 mm Hg 7. Uncontrolled Hypertension (Systolic BP >140 mmHg, Diastolic BP > 90 mmHg). 8. Sick sinus syndrome, Mobitz type 2 second degree AV block or third degree AV block unless controlled with an artificial implantable pacemaker 9. NYHA functional class IV symptoms 10. Treatment with an excluded medication (see Excluded Medications below) 11. Myocardial infarction or coronary artery intervention (CABG or angioplasty) within three months 12. Unstable angina pectoris 13. Presence of any progressive systemic disease that would be expected to impact the patient's outcome over the time course of the study 14. Uncorrected endocrine disorders including primary aldosteronism, pheochromocytoma, hyperthyroidism, hypothyroidism, brittle type 1 diabetes mellitus 15. Evidence of significant renal disease (serum creatinine > 2.5 mg/dl), or hepatic disease (transaminase level > three fold higher than laboratory normal) 16. Symptomatic peripheral vascular disease 17. Inability or unwillingness to cooperate with study or give written informed consent



Primary Contact:

Principal Investigator
Mark Munger, PharmD
Professor, Pharmacotherapy

Backup Contact:


Location Contact:

Salt Lake City, Utah 84112
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.